BELTSVILLE, Md. May 30, 2024 -’ NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on developing pioneering immunotherapies to treat cancer and other immune-related diseases, disclosed recent findings from their Phase 1b clinical trial combining NC410, a LAIR-2 fusion protein, with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Study and Clinical Findings
The Phase 1b portion of the Phase 1b/2 study evaluated the combination’s effectiveness in patients with immune checkpoint inhibitor (ICI)-naïve and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer ’ conditions known for their resistance to standard therapies. According to Dr. Eric S. Christenson, Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and investigator of the trial, the combination therapy demonstrated promising clinical activity in these challenging cases.
NC410 and Pembrolizumab: Mechanism of Action
NC410 is designed as a LAIR-2 fusion protein aimed at inhibiting the immunosuppressive role of LAIR-1. By pairing NC410 with pembrolizumab, which is a PD-1 inhibitor, the study seeks to potentiate the body’s immune response against tumor cells. The synergistic effect observed suggests a new horizon in treating cancers unresponsive to existing immune checkpoint inhibitors.
Previous Research and Financial Performance
NextCure has consistently advanced its research on T cell inhibitors. Earlier this year, the company published a study in Science Advances outlining the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in inhibiting T cell activity. This research underscores the company’s commitment to understanding and overcoming immune checkpoints that reduce the efficacy of T cell-based cancer therapies.
In terms of financial performance, the company reported its full-year 2023 financial results in March. The detailed analysis highlighted NextCure’s investments in ongoing clinical trials and research, underscoring their near-term focus on bringing novel immunotherapies to market.
Conclusion and Future Directions
The encouraging data from the Phase 1b study of NC410 in combination with pembrolizumab accentuate NextCure’s capability in pioneering new approaches to treat refractory cancers. As we await further results from the ongoing Phase 1b/2 study, these initial findings hold promise for future clinical applications and enhanced treatment regimens for colorectal and ovarian cancer patients.
NextCure’s multifaceted research and continued financial stability both reflect and support its enduring mission to innovate in the field of cancer immunotherapy. The company remains at the forefront of developing cutting-edge treatment solutions for some of the most challenging cancer types.
Comments